Tanezumab for the treatment of pain from osteoarthritis of the knee

New England Journal of Medicine

Volumn 363, Issue 16, 2010, Pages 1521-1531

  Lane, Nancy E ^a   Schnitzer, Thomas J ^b   Birbara, Charles A ^c   Mokhtarani, Masoud ^d   Shelton, David L ^d   Smith, Mike D ^e   Brown, Mark T ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d Rinat Neuroscience   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TANEZUMAB; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR RECEPTOR;

ADULT; AGED; ALLODYNIA; ANALGESIC ACTIVITY; APPENDICITIS; ARTICLE; BACTERIAL ARTHRITIS; BREAST CANCER; BURNING SENSATION; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSESTHESIA; FEMALE; HEADACHE; HUMAN; HYPERESTHESIA; HYPESTHESIA; JOINT STIFFNESS; KNEE FUNCTION; KNEE OSTEOARTHRITIS; KNEE PAIN; LEG PAIN; MAJOR CLINICAL STUDY; MALE; NEURALGIA; NEURITIS; NEUROLOGIC EXAMINATION; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PALLANESTHESIA; PARESTHESIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SENSORY DYSFUNCTION; SOMATOSENSORY DISORDER; SYNCOPE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VERTEBRAL CANAL STENOSIS; VISUAL ANALOG SCALE; WALKING; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; OSTEOARTHRITIS, KNEE; PAIN; PAIN MEASUREMENT; PHASE 2 CLINICAL TRIAL; RESPIRATORY TRACT INFECTIONS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HEADACHE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN; PAIN MEASUREMENT; PARESTHESIA; RECEPTOR, NERVE GROWTH FACTOR; RESPIRATORY TRACT INFECTIONS; WALKING;

EID: 77957934893     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0901510     Document Type: Article

References (38)

1. Woolf CJ, Safieh-Garabedian B, Ma QP, Crilly P, Winter J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 1994;62:327-31. (Pubitemid 24306656)
2. McMahon SB. NGF as a mediator of inflammatory pain. Philos Trans R Soc Lond B Biol Sci 1996;351:431-40.
3. Skaper SD. The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol Disord Drug Targets 2008;7:46-62.
4. Petruska JC, Mendell LM. The many functions of nerve growth factor: multiple actions on nociceptors. Neurosci Lett 2004; 361:168-71.
5. Barker PA, Murphy RA. The nerve growth factor receptor: a multicomponent system that mediates the actions of the neurotrophin family of proteins. Mol Cell Biochem 1992;110:1-15.
6. Frade JM, Barde YA. Nerve growth factor: two receptors, multiple functions. Bioessays 1998;20:137-45.
7. Nicol GD, Vasko MR. Unraveling the story of NGF-mediated sensitization of nociceptive sensory neurons: ON or OFF the Trks? Mol Interv 2007;7:26-41.
8. Hao J, Ebendal T, Xu X, Wiesenfeld-Hallin Z, Eriksdotter Jönhagen M. Intracerebroventricular infusion of nerve growth factor induces pain-like response in rats. Neurosci Lett 2000;286:208-12.
9. Ruiz G, Ceballos D, Baños JE. Behavioral and histological effects of endoneurial administration of nerve growth factor: possible implications in neuropathic pain. Brain Res 2004;1011:1-6.
10. Halliday DA, Zettler C, Rush RA, Scicchitano R, McNeil JD. Elevated nerve growth factor levels in the synovial fluid of patients with inflammatory joint disease. Neurochem Res 1998;23:919-22. (Pubitemid 28178167)
11. Friess H, Zhu ZW, di Mola FF, et al. Nerve growth factor and its high-affinity receptor in chronic pancreatitis. Ann Surg 1999;230:615-24.
12. Miller LJ, Fischer KA, Goralnick SJ, et al. Nerve growth factor and chronic prostatitis/ chronic pelvic pain syndrome. Urology 2002;59:603-8.
13. McMahon SB, Bennett DL, Priestley JV, Shelton DL. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat Med 1995;1:774-80.
14. Ramer MS, Bisby MA. Adrenergic innervation of rat sensory ganglia following proximal or distal painful sciatic neuropathy: distinct mechanisms revealed by anti-NGF treatment. Eur J Neurosci 1999;11: 837-46.
15. Zahn PK, Subieta A, Park SS, Brennan TJ. Effect of blockade of nerve growth factor and tumor necrosis factor on pain behaviors after plantar incision. J Pain 2004;5:157-63. (Pubitemid 38879394)
16. Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci 2006; 27:85-91.
17. Dray A, Read SJ. Arthritis and pain: future targets to control osteoarthritis pain. Arthritis Res Ther 2007;9:212.
18. Dillon CF, Rasch EK, Gu Q, Hirsch R. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991-94. J Rheumatol 2006;33:2271-9.
19. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis. II. OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16:137-62.
20. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a populationbased case-control study. Arch Intern Med 2005;165:978-84. (Pubitemid 40638117)
21. Whelton A. Renal and related cardiovascular effects of conventional and COX-2- specific NSAIDs and non-NSAID analgesics. Am J Ther 2000;7:63-74.
22. Bjordal JM, Ljunggren AE, Klovning A, Slørdal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: metaanalysis of randomised placebo controlled trials. BMJ 2004;329:1317.
23. Bjordal JM, Klovning A, Ljunggren AE, Slørdal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. Eur J Pain 2007;11:125-38.
24. Hawker GA. Who, when, and why total joint replacement surgery? The patient's perspective. Curr Opin Rheumatol 2006; 18:526-30.
25. Abdiche YN, Malashock DS, Pons J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci 2008;17:1326-35.
26. Hefti F, Mokhtarani M, Gray M, Zhao C, Chan C. RN624 (anti-NGF) reduces pain and improves function in subjects with moderate to severe pain from osteoarthritis of the knee. J Pain 2006;7:Suppl:S45. abstract.
27. Lane N, Webster L, Lu S, Gray M, Hefti F, Walicke P. RN624 (anti-NGF) improves pain and function in subjects with moderate knee osteoarthritis: a phase I study. Arthritis Rheum 2005;52:Suppl: S461. abstract.
28. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49. (Pubitemid 16049266)
29. Pham T, van der Heijde D, Altman RD, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004;12:389-99.
30. Shapiro AM, Benedict RH, Schretlen D, Brandt J. Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. Clin Neuropsychol 1999;13:348-58.
31. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: L. Erlbaum, 1988.
32. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21.
33. Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres? Pain 1997;72:95-7.
34. Rowbotham MC. What is a "clinically meaningful" reduction in pain? Pain 2001; 94:131-2.
35. Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain 2004;8:283-91. (Pubitemid 38859657)
36. Shelton DL, Zorbas M, Bales R, Rogers B, Pons J. Preclinical safety evaluation of PF04383119 after single and multipledose administration in monkeys. Anesthesiology 2008;109:A597 (Web only). abstract. (Accessed July 30, 2010, at http://www .asaabstracts.com/strands/asaabstracts/ searchArticle. htm;jsessionid=618E87D0E 0ABC77F4B2A108910544EA7?index=1& highlight=false&highlightcolor=1&bold= true&italic=false.)
37. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354:795-808.
38. Kahan A, Uebelhart D, De Vathaire F, Delmas PD, Reginster JY. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009;60: 524-33.